Spektakulärer Deal als Value-Treiber

Juniper Pharmaceuticals (Nasdaq: JNP) ist wieder ein Konzern, auf den ich durch sharedeals.de aufmerksam geworden bin. Ich habe ihn mir angesehen und möchte nun einen kleinen Artikel darüber schreiben.

Daré Bioscience, Inc. (DARE) veröffentlichte diese News, stieg darauf fett und wurde kurz im sharedeals.de Live-Chat angesprochen. Ich sah mir beide Werte an und hier nochmal die News die Juniper dazu veröffentlichte:

Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience

Company Eligible to Receive Up to $43.75 Million in Milestones for Each IVR Candidate, Plus Royalties on Future Sales-

BOSTON, April 25, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business Juniper Pharma Services (JPS), today announced an exclusive worldwide license agreement with Daré Bioscience for the development and commercialization of the Company's intravaginal ring (IVR) technology platform, including its three preclinical IVR candidates targeting unmet needs in women's health. Under the agreement, Daré will be responsible for conducting all research, development, and commercial activities for this program.

Under the terms of the agreement, Juniper will provide Daré with an exclusive, worldwide, royalty-bearing license to research, develop and commercialize Juniper's IVR platform. In exchange, Juniper will receive a one-time upfront payment of $250,000 from Daré, and annual license maintenance fees of $50,000 to $100,000. In addition, Juniper is entitled to potential future clinical and regulatory development milestone payments of up to $13.5 million and sales milestone payments of up to $30.25 million, for a total of $43.75 million for each IVR candidate. Juniper is also eligible to receive royalties based on future net sales of any of the platform candidates.

"We are excited to have executed on our goal of finding a suitable partner to advance our innovative IVR portfolio, which will allow us to focus our efforts and resources on our core businesses, JPS and CRINONE®, in line with our strategic vision," said Alicia Secor, Juniper's President and CEO. "We are continuing to work with our advisor Rothschild to explore strategic alternatives as we seek to build additional value for our shareholders."

Ms. Secor added, "We are thrilled to be partnering with Daré, an established leader in the women's health space, as they work toward advancing each of our IVR candidates. The Daré team has a solid track record in developing women's reproductive health products and appreciated the potential of the platform to address significant unmet needs in women's health."

"We see great potential in this promising technology with established compelling preclinical results in a model that we believe will translate readily to study in humans and into intellectual property supportive of further development," said Sabrina Martucci Johnson, President and Chief Executive Officer at Daré Bioscience. "The IVR pipeline is an ideal fit to our pipeline of innovative products designed to deliver differentiated therapies to women worldwide, and we look forward to advancing these IVR product candidates into the clinic." 

About the Intravaginal Ring Technology
Juniper's differentiated development platform leverages IVR technology for the targeted, sustained delivery of new formulations of existing pharmaceuticals with the potential to offer multiple benefits to patients with unmet needs in women's health. Current 505(b)(2) candidates include JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

core businesses (ir.juniperpharma.com/static-files/248a070d-f513-4ea5-9b01-53cd791eb7db)

• CRINONE® (progesterone gel) franchise and
• fee-for-service pharmaceutical development and manufacturing business Juniper Pharma Services (JPS)
• IVR Pipeline

Crinone (CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S; Juniper manages supply chain) ist der Garant für einen stabilen Cash Flow. Die bekannten Sorgen der Kapitalbeschaffung anderer BioTech-Werte kennt Juniper somit nicht.

Juniper Pharma Services: Science-led, fee-for-service contract development and manufacturing organization based in U.K.

•Revenues up 38% year-over-year in Q3 2017

•Expanding service offerings to continue growth trajectory

Am 10. Mai hat Juniper Zahlen für das erste Quartal vermeldet. 

Das Unternehmen schreibt Gewinne und verbrennt kaum noch Gelder. Im Jahresvergleich stiegen die Umsätze um 38%. Insbesondere die Partnerschaft mit Merck KGaA trägt Früchte.

Am 31. Mai soll der Conference Call erfolgen. Das sollte dem Unternehmen und dem Aktienkurs helfen. Ausdrücklich werden nochmal die signifikanten Meilensteinzahlen aus dem IVR Deal angesprochen, mehr als 120 Mio USD. Das sind mehr als 150% der aktuellen Marktkapitalisierung abzgl. Cash.

Fazit:

Die Juniper Pharma steht solide da. Das Kerngeschäft wächst mit mehr als 25% pro Jahr. Der Vertrag mit Merck für Crinone® wurde gerade bis 2024 verlängert und sorgt für stabile Einnahmen. Die IVR Geschäfte kommen on top.

Der nächste Artikel wird über AGTC oder Idea Fabrik plc sein. In den nächsten Wochen sollten da wieder News kommen.